Objective
RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk groups. RESCEU brings together academia, national public health agencies and EFPIA with proven expertise and a strong track record in RSV research. The academic partners are leaders in RSV epidemiology, clinical RSV research, health economics, and vaccinology; and key opinion leaders with advisory roles in European and national public health bodies, health technology agencies and vaccine advisory groups. EFPIA participants (AZ, GSK, JPNV, Novavax, Pfizer, and SP) have active clinical research programmes to develop lead candidates for treatment and prevention of RSV in infants, adults and the elderly. As part of RESCEU, EFPIA participants will contribute expertise in a wide range of fields including infectious disease, clinical medicine, immunology, epidemiology, biostatistics, biomarker development, global health, and health economics. RESCEU’s aim is to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics. RESCEU aims to provide sustainable longer term impact on RSV disease burden and thus make a significant contribution to improved health and wellbeing in Europe.
The project will comprise 6 work packages. WP 1-3 will identify and marshal data from large-scale systematic reviews of epidemiological and cost studies, disease registries, linked routine (national) healthcare and claims datasets and will establish a framework for and assemble data from RSV surveillance in Europe to estimate RSV disease burden on health services and inform economic models.
Fields of science
Programme(s)
Funding Scheme
IMI2-RIA - Research and Innovation actionCoordinator
EH8 9YL Edinburgh
United Kingdom
See on map
Participants (18)
2000 Antwerpen
See on map
3584 CX Utrecht
See on map
OX1 2JD Oxford
See on map
Participation ended
28006 Madrid
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
SW7 2AZ London
See on map
15703 Santiago De Compostela
See on map
20520 Turku
See on map
3721 MA Bilthoven
See on map
2300 Kobenhavn S
See on map
9713 GZ Groningen
See on map
35127 Padova
See on map
151 85 Sodertaelje
See on map
CT13 9NJ Sandwich
See on map
1330 Rixensart
See on map
69007 Lyon
See on map
2340 Beerse
See on map
20878 Gaithersburg
See on map
08007 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.